PSA on TRT: What Every Man Over 40 Should Know About Prostate Monitoring

What PSA measures and why it matters on TRT

PSA on TRT is the prostate-specific antigen blood test, run alongside the rest of your TRT lab panel, used to screen for prostate disease in men over 40 on testosterone therapy. PSA is a protein produced almost exclusively by prostate epithelial cells. A small amount leaks into circulation and is measurable in serum.

PSA goes up for several reasons — benign prostatic hyperplasia (BPH), prostatitis, recent ejaculation, recent digital rectal exam, urinary tract infection, vigorous cycling, and prostate cancer. It is a sensitive but non-specific marker. A single elevated value does not mean cancer; a stable normal value does not perfectly rule it out.

On TRT, PSA matters for two reasons. First, testosterone therapy can produce a small, predictable rise in PSA during the first months of treatment, and that rise needs to be distinguished from a pathologic trend. Second, men on TRT skew older, and prostate cancer incidence rises sharply after age 50. PSA monitoring on TRT is age-appropriate cancer screening run on a tighter schedule because the dose is being adjusted in real time.

For broader monitoring context, see the TRT blood work schedule and the blood work pillar guide.

What TRT actually does to PSA

Restoring testosterone in a hypogonadal man typically produces a small, one-time PSA bump during the first 3-6 months, after which PSA stabilizes at a new baseline. The size of the rise varies, but most published studies and meta-analyses report an average increase in the range of 0.2 to 0.5 ng/mL.

A meta-analysis by Calof et al. in Journals of Gerontology: Medical Sciences (2005) pooled placebo-controlled testosterone trials and reported a small but statistically significant PSA rise on testosterone compared with placebo, well within ranges that triggered no biopsy in most men. The pattern is consistent across more recent trials, including TRAVERSE (Lincoff et al., NEJM 2023, PMID 37326322), where mean PSA changes were modest.

The clinical signal: a small early rise is biology, not alarm. A continued rise after 6 months, or a single jump greater than 1.4 ng/mL within any 12-month window, is what triggers further workup under Endocrine Society 2018 guidance (Bhasin et al., DOI 10.1210/jc.2018-00229).

The androgen saturation model

Why does PSA rise only a little on TRT, even though testosterone is going up dramatically? The answer is the androgen saturation model, articulated by Morgentaler and colleagues over the last two decades.

Prostate androgen receptors are saturated at relatively low serum testosterone — often cited around 250 ng/dL. Above that point, additional testosterone produces little additional androgen-driven prostate stimulation. Restoring a hypogonadal man from a total T of 200 ng/dL to a healthy 700 ng/dL crosses the saturation point and produces the small initial PSA rise. Pushing further does not produce a proportional further rise.

This model explains why decades of TRT clinical experience have not produced a clear dose-response curve for prostate cancer risk in eugonadal men, and why supraphysiological doses do not produce dramatic PSA spikes in the way an older "more testosterone equals more prostate stimulation" model would predict. It is also why the data summarized below from TRAVERSE — using physiologic transdermal restoration — looks the way it does.

TRAVERSE and prostate cancer: what the 2023 data showed

The TRAVERSE trial (Lincoff et al., New England Journal of Medicine, 2023, PMID 37326322) is the most relevant modern dataset on TRT and prostate cancer. It enrolled 5,246 men aged 45-80 with hypogonadism and pre-existing or high cardiovascular risk, randomizing them to transdermal testosterone gel or placebo. Follow-up averaged about 33 months. While its primary endpoint was cardiovascular safety (covered in our TRAVERSE explainer), the trial pre-specified prostate safety outcomes.

The prostate findings from TRAVERSE:

• High-grade prostate cancer: 5 cases in the testosterone group (0.19%) vs 3 in placebo (0.12%) — not statistically significant.
• Any prostate cancer: Overall incidence numerically similar between arms.
• Acute urinary retention and BPH-related events: small numerical excess in the testosterone arm, consistent with prior literature on TRT and benign prostate effects.
• PSA changes: small mean rise from baseline in the testosterone group, in line with the saturation-model expectation.

TRAVERSE is the largest randomized cardiovascular safety trial of testosterone therapy ever conducted, and it tested transdermal gel in older men with risk factors — a population enriched for incidental prostate findings. The absence of a prostate cancer signal at the trial-level scale is the strongest contemporary evidence against the historical concern that TRT "feeds" prostate cancer.

What TRAVERSE does not say: it does not say PSA monitoring is unnecessary. It does not say men with active untreated prostate cancer should start TRT. It does not extrapolate to supraphysiological injection doses — gel at physiologic restoration is the trial protocol, not 200 mg/week IM. PSA monitoring remains the standard of care.

AUA and Endocrine Society monitoring schedules

Two professional society guidelines define current TRT prostate monitoring practice in the United States. They agree on the basics.

Endocrine Society 2018 (Bhasin et al.)

The Endocrine Society's clinical practice guideline (Journal of Clinical Endocrinology & Metabolism, 2018, DOI 10.1210/jc.2018-00229) recommends:

• Baseline PSA and digital rectal exam (DRE) before starting TRT in men over 40
• Repeat PSA at 3-12 months after starting TRT
• Then per standard prostate cancer screening guidelines for the man's age and risk profile
• Urology referral if PSA increases > 1.4 ng/mL within 12 months, confirmed PSA > 4.0 ng/mL, abnormal DRE, or symptoms of lower urinary tract obstruction

AUA 2018 (updated 2024)

The American Urological Association's testosterone deficiency guideline (Mulhall et al., 2018, with 2024 amendment available via auanet.org) is operationally consistent. Key positions:

• TRT does not increase prostate cancer risk in men without a prior diagnosis
• PSA monitoring should follow the same age-appropriate prostate cancer screening recommendations as for men not on TRT, with an additional check 3-12 months after TRT initiation
• Men with a history of treated prostate cancer may be candidates for TRT in selected, individualized circumstances with urology involvement

Putting the schedules side by side

PSA velocity and the 1.4 ng/mL threshold

Three numbers do most of the work in TRT prostate monitoring. They are screening rules, not diagnoses.

1. Confirmed PSA above 4.0 ng/mL. A single elevated PSA should be repeated in 4-6 weeks under standardized conditions. A confirmed value above 4.0 ng/mL warrants urology evaluation regardless of TRT context.
2. PSA velocity greater than 1.4 ng/mL in 12 months. Endocrine Society 2018 specifically calls out a rise greater than 1.4 ng/mL within any 12-month period after starting TRT as a referral trigger.
3. Lower thresholds in higher-risk men. African ancestry, first-degree family history of prostate cancer, or known prostate findings shift the conversation earlier — often a baseline or follow-up PSA above 3.0 ng/mL prompts evaluation.

Modern urology rarely treats velocity in isolation. A PSA that goes from 0.6 to 2.0 over a year is a different conversation than 4.0 to 5.4 over the same interval, even though both crossed the 1.4 ng/mL bar. Free/total PSA ratio, prostate size, age, and risk factors all weigh in. The 1.4 ng/mL rule is a tripwire that brings a urologist into the room — what happens next is a urologist's decision.

Pre-TRT prostate evaluation

Before a first TRT prescription, men over 40 should have a baseline PSA and a documented DRE. This is true under both the Endocrine Society and AUA guidelines. The reason is simple: TRT does not cause prostate cancer in the modern saturation-model understanding, but starting TRT in a man with undiagnosed clinically significant prostate cancer can muddy the picture.

Baseline findings that typically delay or complicate a TRT start until urology weighs in:

• PSA above 4.0 ng/mL (or above 3.0 ng/mL in higher-risk men)
• An abnormal DRE — a nodule, induration, or asymmetric enlargement
• Prior abnormal PSA or imaging that has not been resolved
• A known prostate biopsy with atypical small acinar proliferation (ASAP) or high-grade prostatic intraepithelial neoplasia (HGPIN) without follow-up
• Symptoms of lower urinary tract obstruction severe enough to warrant evaluation independent of TRT

None of these are absolute lifetime contraindications to TRT. They are reasons to evaluate and document the prostate before adding testosterone to the picture.

TRT after a prostate cancer diagnosis

For decades, prior prostate cancer was treated as an absolute contraindication to TRT. That position has softened in select circumstances, though it remains a urology-driven decision and never one to make from a blog article.

The AUA 2018 guideline (updated 2024) states that TRT may be considered in selected men with a history of treated localized prostate cancer who are symptomatic from hypogonadism, after appropriate discussion of risks. Practical features of cases where TRT has been considered:

• Treated, low-risk localized disease — Gleason 6 or favorable intermediate-risk Gleason 3+4
• Undetectable PSA after definitive treatment (prostatectomy or radiation)
• An adequate disease-free interval, often 1-2 years post-treatment
• Significant symptomatic hypogonadism not resolved by lifestyle measures
• Shared decision-making with the urologist or oncologist who treated the cancer
• Tighter PSA monitoring schedule than a standard TRT patient

Active untreated prostate cancer remains a contraindication. Men on active surveillance for very-low-risk disease are a gray zone — some urologists allow TRT; many do not. The defining feature of all of these conversations is that they happen in a urology clinic with full chart review, not in a TRT telehealth intake.

Common pitfalls and false alarms

Most PSA "scares" on TRT turn out to be one of the same handful of confounders. Knowing the list saves anxiety and unnecessary biopsies.

• Recent ejaculation. PSA can be transiently elevated for 24-48 hours after ejaculation. Standard advice is 48 hours of abstinence before a PSA draw.
• Recent DRE or prostate manipulation. Always draw PSA before a DRE in the same visit.
• Active urinary tract infection or prostatitis. PSA can rise dramatically — sometimes into the double digits — and normalizes after treatment.
• Vigorous cycling. Long rides on an aggressive saddle in the day or two before a draw can elevate PSA.
• Lab assay differences. Different platforms can yield slightly different absolute values. Trends are most reliable when run on the same platform consistently.
• Recent catheterization, cystoscopy, or instrumentation. These elevate PSA for days to weeks.
• Hydration and timing. Less impactful than the above, but consistent timing reduces noise across draws.

A brief scenario

A 52-year-old man four months into TRT with a baseline PSA of 0.9 ng/mL has a follow-up PSA of 1.3 ng/mL drawn the morning after a long bike ride. His prescriber repeats the draw two weeks later under standard conditions: 1.0 ng/mL. The original elevation was a cycling artifact stacked on the expected small TRT-related rise. No urology referral, no biopsy, monitoring continues on schedule. This pattern is representative.

When your prescriber refers to a urologist

These are the scenarios where the next call from your TRT prescriber is going to be a urology referral, not a protocol tweak.

1. Confirmed PSA greater than 4.0 ng/mL, regardless of starting value
2. Confirmed PSA greater than 3.0 ng/mL in a man with African ancestry or a first-degree family history of prostate cancer
3. PSA velocity greater than 1.4 ng/mL within any 12-month period after starting TRT
4. An abnormal DRE — nodule, induration, asymmetry — at any point
5. New lower urinary tract symptoms (poor stream, hesitancy, urgency, retention) that are not explained by another cause
6. Hematuria (blood in urine) at any time
7. Bone pain or other systemic symptoms that warrant cancer workup

Most men on TRT will never hit these triggers. The system is designed so that, if they do, the response is fast and the workup is in the hands of a specialist. PSA monitoring is the surveillance layer that makes that fast handoff possible.

The bottom line

TRT does not appear to cause prostate cancer in eugonadal men. The 2023 TRAVERSE trial, the largest randomized testosterone safety study to date, found no significant signal for high-grade disease over 33 months in 5,246 older men with cardiovascular risk. PSA still matters because TRT can unmask undiagnosed disease and because age-appropriate prostate screening is the standard of care for the men taking TRT.

The monitoring framework is simple: baseline PSA and DRE before starting, a recheck at 3-12 months, then per standard screening guidelines, with urology referral if PSA crosses 4.0 ng/mL, rises more than 1.4 ng/mL in a year, or any DRE finding turns up. Most men sit comfortably inside that framework with no action beyond a yearly draw.

If you want broader context on how this fits with the rest of TRT lab work, start with the TRT blood work schedule, then read the TRAVERSE trial explained for the cardiovascular and prostate safety data, and the hematocrit on TRT companion for the other commonly-flagged lab on TRT. If you are considering pausing therapy, see coming off TRT. The full pillar lives at the blood work guide.